igf-1 lr3 human clinical trial in Aesthetic and Anti-Aging Medicine: Benefits and Risks Human LR3 IGF-I Recombinant Protein
Description
Kuruma Y
The 3-week stay and treatment in the sanatorium (high level of solar insolation) demonstrated reduction of pain intensity according to VAS (p = 0,017) and fatigue according to BRAF-NRS questionnaire scales: severity (p = 0,041) and NRS-effect (p = 0,029) only in patients from group II
Systematic review of NTRK 1/2/3 fusion prevalence pan-cancer and across solid tumours
[DOI] [PubMed] [Google Scholar] 10.Postuma RB, Aarsland D, Barone P, et al
